Anticancer Medications
Anticancer Medications - Related Videos
01:49
An Assay To Evaluate the Anticancer Effects of Lactobacillus Cell-Free Supernatant
0 Views •
2025
This video demonstrates an in vitro assay to study the anticancer effects of Lactobacillus cell-free supernatant (LCFS). Upon exposing colorectal cancer spheroids to varying doses of LCFS, the interaction with the bacterial metabolites in LCFS induces apoptosis in the cancer cells, disrupting the spheroid structure and leading to cell death in a dose-dependent manner.
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
04:11
Colony Formation Assay: Assessing the Efficacy of Anticancer Agents on Colony-Forming Lung Cancer Cells
0 Views •
2023
This video describes the colony formation assay, which helps determine lung cancer cells' ability to proliferate indefinitely and form individual colonies. We can analyze the effect of an anticancer agent on the colony-forming cells by analyzing the changes in the number and/or size of the resulting colonies.
06:59
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
0 Views •
Cited by 5 •
2016
This study presents a novel device that offers an easy route to quickly provide medications and fluids in patients with limited or difficult IV access. This small-diameter device is placed in the distal third of the rectum, allowing for ongoing medication and fluids administration.
FAQs
Drug classes target cancer through distinct biological vulnerabilities. Some damage DNA, while others disrupt cell division, inhibit oncogenic signaling, alter hormone stimulation, or activate immune recognition of tumor cells. These differences matter clinically because the selected mechanism must fit the tumor’s biology, and combining complementary mechanisms may improve disease control when a single approach is insufficient.
Molecular biomarkers provide information about tumor characteristics that can guide treatment selection. They help clinicians identify whether a cancer may be suited to a medication aimed at a particular oncogenic signaling pathway or another defined vulnerability. Using this information supports more precise treatment decisions and may help avoid choosing a drug whose mechanism does not match the tumor.
Resistance becomes an important treatment challenge when malignant cells are no longer adequately controlled by a medication. The overview links ongoing drug development with overcoming resistance, indicating that treatment response depends on both the cancer’s biology and its changing behavior. Precision strategies and treatment combinations are therefore investigated to improve durability while limiting unnecessary toxicity.
Clinical selection considers tumor type, disease stage, molecular biomarkers, previous therapy, and the patient’s overall health. These factors determine which mechanism is most appropriate and whether medications should be combined or used sequentially. The resulting regimen is tailored rather than uniform, allowing treatment objectives and anticipated tolerability to guide decisions in clinical oncology.
Clinicians monitor both treatment response and adverse effects throughout care. Response assessment indicates whether malignant disease is being controlled, while adverse-effect monitoring helps evaluate the treatment’s impact on the patient. This information supports ongoing clinical decisions, including whether the selected approach remains appropriate for its intended goal and whether toxicity needs greater consideration.
The intended outcome depends on the clinical setting and the patient’s disease characteristics. Anticancer medications may contribute to curative treatment, help control cancer when elimination is not the immediate objective, or provide symptom relief. Distinguishing these goals helps clinicians interpret treatment response realistically and align medication choices with the broader plan of oncology care.